Adipopharma
2 known investors
AdipoPharma is a French biotech company developing PATAS, a first-in-class stapled peptide insulin sensitizer that targets adipocytes to treat insulin resistance, type 2 diabetes, and associated comorbidities. Its adipocyte-focused approach aims to address the root cause of type 2 diabetes, with its lead drug entering clinical trials in 2025.
Founders & leadership
VM
Vincent MarionFounder, President & CEO
CP
Catherine PerotChief Financial Officer
MJ
Michael J. FareChief Operating Officer
TG
Tarekegn G. HiwotChief Medical Officer
Investors · 2
Frequently asked questions
- What does Adipopharma do?
- AdipoPharma is a French biotech company developing PATAS, a first-in-class stapled peptide insulin sensitizer that targets adipocytes to treat insulin resistance, type 2 diabetes, and associated comorbidities. Its adipocyte-focused approach aims to address the root cause of type 2 diabetes, with its lead drug entering clinical trials in 2025.
- Who founded Adipopharma?
- Adipopharma was founded by Vincent Marion.
- Who are Adipopharma's investors?
- Adipopharma's investors include Good Growth Capital, Newton Biocapital.